FINWIRES · TerminalLIVE
FINWIRES

Amazon AWS Growth Set to Outpace Street on AI Demand, UBS Says

By

Amazon.com's (AMZN) Amazon Web Services growth is expected to continue to be "nonlinear," supported by incremental investments and deals with both OpenAI and Anthropic that are expected to add nearly $200 billion in backlog and accelerate long-term capacity expansion, UBS Securities said in a note Thursday.

The brokerage said it differs meaningfully from the Street on AWS revenue for 2026, at 38% compared to the Street consensus of 26%, which then compounds into 2027 as additional capacity comes online and backlog converts into revenue.

UBS added that its 2027 operating income estimate is hence nearly 39% above consensus. The brokerage believes that the Street will eventually converge toward its more bullish trajectory as AWS scale and demand visibility improve.

Although Amazon shares have rebounded significantly year-to-date, UBS thinks there is still room to outperform. The investment firm believes a premium asset like Amazon should not trade at a discount to the market multiple given its long-term AWS and AI-driven growth profile.

UBS has a buy rating on Amazon and raised the price target to $304 from $301.

Price: $256.63, Change: $+1.26, Percent Change: +0.50%

Related Articles

Wire

New Hope Completes AU$300 Million Convertible Notes Offering

New Hope (ASX:NHC) completed a AU$300 million issuance of 2.625% senior unsecured convertible notes due 2032 and the concurrent repurchase of AU$293.3 million of its existing 2029 convertible notes, according to a Thursday filing with the Australian bourse.The new notes are expected to be listed on the Singapore Exchange Securities Trading on or around Thursday, per the filing.The repurchased 2029 notes, which account for around 98% of the outstanding notes, will be cancelled under their terms, the filing said. The company also plans to redeem the remaining AU$6.7 million of notes at par plus accrued interest prior to maturity.

ASX:NHC
Wire

Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes

Telix Pharmaceuticals (ASX:TLX) said it settled the issue of $600 million in 1.50% convertible notes due 2031, according to a Thursday Australian bourse filing.The convertible notes are expected to be listed on the Official List of the Singapore Exchange Securities Trading on Thursday.In the same filing, the company said that the repurchase of around AU$637 million in principal of the AU$650 million worth of 2.375% convertible bonds due 2029 is "substantially complete."After the repurchase, given that less than 15% in aggregate principal amount of the existing bonds will remain outstanding, Telix said it plans to exercise its right to repurchase and cancel all of the remaining existing bonds at their principal amount.

ASX:TLX
Wire

Century Communities Q1 Adjusted Earnings, Revenue Fall

Century Communities (CCS) reported Q1 adjusted earnings late Wednesday of $0.88 per diluted share, down from $1.39 a year earlier.Three analysts polled by FactSet expected $0.59.Revenue for the three months ended March 31 fell to $789.7 million from $903.2 million a year earlier.Four analysts surveyed by FactSet expected $807.7 million.

$CCS